Company intelligence / Profile preview
Trilo Therapeutics
San Francisco, California, USAtrilotherapeutics.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Preclinical
01
Overview
Developing mirror-image cyclic peptides (Trilomers®) that enable targeted delivery of potent chemotherapy drugs for cancer treatment. Their technology aims to overcome limitations of traditional antibody-drug conjugates by using 100% D-amino acids that are resistant to proteases and exhibit low uptake by renal scavenger receptors.
- Therapeutic areas
- Oncology
- Modalities
- Mirror-image cyclic peptides (Trilomers®)Peptide-drug conjugates
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Trilo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trilo Therapeutics.